ReviewAsian journal of andrology2013
Evolving landscape and novel treatments in metastatic castrate-resistant prostate cancer.
Review in Asian journal of andrology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Insulin-Like Growth Factor 2 mRNA-Binding Protein 2 (IGF2BP2) Promotes Castration-Resistant Prostate Cancer Progression by Regulating AR-V7 mRNA Stability.Cancer reports (Hoboken, N.J.) · 2025Article
- Recombinant Human Clusterin Seals Damage to the Ocular Surface Barrier in a Mouse Model of Ophthalmic Preservative-Induced Epitheliopathy.International journal of molecular sciences · 2023Article
- The Androgen Regulated lncRNANon-coding RNA · 2022Article
- Clusterin, other extracellular chaperones, and eye disease.Progress in retinal and eye research · 2022Review
- Transperineal Parallel Biopsy of the Prostate: A New Approach of Tissue Sampling for Precision Medicine.International journal of general medicine · 2021Article
- RNA-binding protein Musashi2 stabilizing androgen receptor drives prostate cancer progression.Cancer science · 2020Article
- Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment.BMC urology · 2016Article
- Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.European urology · 2015Review
- Clusterin Seals the Ocular Surface Barrier in Mouse Dry Eye.PloS one · 2015Article
- Cullin-1 promotes cell proliferation via cell cycle regulation and is a novel in prostate cancer.International journal of clinical and experimental pathology · 2015Article
- From bench to bedside: immunotherapy for prostate cancer.BioMed research international · 2014Review
- The many faces of neuroendocrine differentiation in prostate cancer progression.Frontiers in oncology · 2014Review
- Combination of the PI3K inhibitor ZSTK474 with a PSMA-targeted immunotoxin accelerates apoptosis and regression of prostate cancer.Neoplasia (New York, N.Y.) · 2013Article
- Real-World Corticosteroid Utilization Patterns in Patients with Metastatic Castration-Resistant Prostate Cancer in 2 Large US Administrative Claims Databases.American health & drug benefits · 2013Article
- Global advances in prostate cancer diagnosis and therapy.Asian journal of andrology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Treatment options for castrate-resistant prostate cancer (CRPC) have advanced in recent years and significantly improved the outlook for patients with this aggressive and lethal disease. Further understanding of the biology of CRPC has led to several new targeted therapies and continues to emphasize the importance of androgen receptor (AR) directed therapy. The treatment landscape is rapidly changing and further biologically rationale, biomarker-based ongoing clinical trials are needed. We review the recent results of major clinical trials in CRPC. New and investigational agents now in clinical evaluation are reviewed including inhibitors of angiogenesis, microtubules, chaperones, AR and intracellular kinases, as well as immunotherapy, radiopharmaceuticals and bone-targeted agents. The recent improvement in prognosis for CRPC brings continued optimism for further improvements. Thoughtful planning of clinical trials and further understanding of the mechanisms of resistance to therapies will allow for continued progress in patient care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.